Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    22939997 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Drug: Nab-Paclitaxel and Gemcitabine

Indicates status has not been verified in more than two years